NCT07902583
Pancoronavirus Vaccine Study in Healthy Adults Ages 18-55
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Number of participants with solicited local and systemic reactogenicity events from the time of each study vaccination through 14 days after each study vaccination by dosage amount
Timeframe: Up to Day 15, up to Day 43
Number of participants with study product-related and unrelated unsolicited non-serious adverse events from the time of the first study vaccination through approximately 28 days after the last study vaccination (Day 57) by dosage amount
Timeframe: Up to Day 57
Number of participants with clinical safety laboratory adverse events from the time of each study vaccination through approximately 28 days after each study vaccination by dosage amount
Timeframe: Up to Day 29, up to Day 57
Number of participants with AESIs, SAEs, MAAEs, NOCMCs, and PIMMCs at any time following the first vaccination through 12 months following the last dose received by dosage amount
Timeframe: Up to Day 394
Secondary (3)
Geometric mean ID50 titers (IU50/mL) of neutralizing antibody levels against multiple betacoronaviruses before vaccination and 28 days (Day 57) following second vaccination
Geometric mean fold rise (ID50) titers of neutralizing antibody levels against multiple betacoronaviruses from before vaccination to 28 days (Day 57) following second vaccination
Binding titers (BAU/mL) of antibodies to SARS-CoV-2 Spike (WA-1 isolate) protein from plasma specimens before vaccination to 28 days (Day 57) following second vaccination
Arms and interventions
Cohort 1AActive comparator
Cov-RBD-scNP-001 20 mcg
Cohort 1BActive comparator
Cov-RBD-scNP-001 20 mcg + ACU-026-001-1 1 mg
Cohort 2AActive comparator
Cov-RBD-scNP-001 50 mcg
Cohort 2BActive comparator
Cov-RBD-scNP-001 50 mcg + ACU-026-001-1 1 mg
Cohort 3AActive comparator
Cov-RBD-scNP-001 10 mcg
Cohort 3BActive comparator
Cov-RBD-scNP-001 10 mcg + ACU-026-001-1 1 mg
Biologicals: Cov-RBD-scNP-001, ACU-026-001-1